Literature DB >> 26137398

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.

Silvia Pesce1, Giovanna Tabellini2, Claudia Cantoni3, Ornella Patrizi2, Daniela Coltrini2, Fabio Rampinelli4, Jessica Matta5, Eric Vivier5, Alessandro Moretta1, Silvia Parolini6, Emanuela Marcenaro7.   

Abstract

In this study the phenotype and function of tumor-associated NK cells from peritoneal fluids of a selected cohort of patients with seropapillary ovarian carcinoma were analyzed. In > 50% of these patients, the expression of the activating receptor NKp30 in tumor-associated NK cells was substantially reduced as compared to autologous peripheral blood (PB) NK cells. The impaired expression of this receptor was associated with the presence of one of its cellular ligands (B7-H6), which was detectable as a surface/cytosolic molecule in tumor cells and as a soluble molecule in the peritoneal fluid. NK cells from patients expressing this NKp30low phenotype displayed an impaired interferon-gamma (IFNγ) production and cytolytic function when tested against target cells expressing surface B7-H6. Our data also suggest that in these patients, the defective expression and function of NKp30 may be induced by the chronic engagement of this receptor by soluble B7-H6 or by tumor cells expressing this ligand. The impairment of NK cell functions described herein could represent a novel mechanism by which the tumor microenvironment may contribute to the escape from immune surveillance.

Entities:  

Keywords:  B7-H6; NK cells; NKp30; mechanism of escape; ovarian carcinoma

Year:  2015        PMID: 26137398      PMCID: PMC4485754          DOI: 10.1080/2162402X.2014.1001224

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  53 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

Review 2.  Role of chemokines in the biology of natural killer cells.

Authors:  Michael J Robertson
Journal:  J Leukoc Biol       Date:  2002-02       Impact factor: 4.962

3.  Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire.

Authors:  J J Campbell; S Qin; D Unutmaz; D Soler; K E Murphy; M R Hodge; L Wu; E C Butcher
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

4.  The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues.

Authors:  Silvia Parolini; Amerigo Santoro; Emanuela Marcenaro; Walter Luini; Luisa Massardi; Fabio Facchetti; David Communi; Marc Parmentier; Alessandra Majorana; Marina Sironi; Giovanna Tabellini; Alessandro Moretta; Silvano Sozzani
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 5.  In the thick of the fray: NK cells in inflamed tissues.

Authors:  Emanuela Marcenaro; Mariella Della Chiesa; Bruna Ferranti; Alessandro Moretta
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

6.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

7.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

8.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

Review 9.  NK cell recognition of non-classical HLA class I molecules.

Authors:  M López-Botet; M Llano; F Navarro; T Bellón
Journal:  Semin Immunol       Date:  2000-04       Impact factor: 11.130

10.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

View more
  67 in total

1.  CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.

Authors:  Bérengère Salomé; Alejandra Gomez-Cadena; Romain Loyon; Madeleine Suffiotti; Valentina Salvestrini; Tania Wyss; Giulia Vanoni; Dan Fu Ruan; Marianna Rossi; Alessandra Tozzo; Paolo Tentorio; Elena Bruni; Carsten Riether; Eva-Maria Jacobsen; Peter Jandus; Curdin Conrad; Manfred Hoenig; Ansgar Schulz; Katarzyna Michaud; Matteo Giovanni Della Porta; Silvia Salvatore; Ping-Chih Ho; David Gfeller; Adrian Ochsenbein; Domenico Mavilio; Antonio Curti; Emanuela Marcenaro; Alexander Steinle; Amir Horowitz; Pedro Romero; Sara Trabanelli; Camilla Jandus
Journal:  Blood Adv       Date:  2019-11-26

Review 2.  The B7 Family Member B7-H6: a New Bane of Tumor.

Authors:  Ying Chen; Jun Mo; Xi Jia; Yang He
Journal:  Pathol Oncol Res       Date:  2017-10-31       Impact factor: 3.201

3.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

4.  Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer.

Authors:  Jing Sun; Hong Tao; Xiaoning Li; Lu Wang; Jie Yang; Pingping Wu; Yaqin Zhang; Yundi Guo
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

5.  Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer.

Authors:  Damien J Zanker; Katie L Owen; Nikola Baschuk; Alex J Spurling; Belinda S Parker
Journal:  Cancer Immunol Immunother       Date:  2021-01-15       Impact factor: 6.968

Review 6.  Tumor-Infiltrating Natural Killer Cells.

Authors:  Beatriz Cózar; Marco Greppi; Sabrina Carpentier; Emilie Narni-Mancinelli; Laura Chiossone; Eric Vivier
Journal:  Cancer Discov       Date:  2020-12-04       Impact factor: 39.397

7.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma.

Authors:  Fabio Morandi; Loredana Amoroso; Alessandra Dondero; Roberta Castriconi; Stefano Parodi; Roberto Luksch; Fiorina Casale; Aurora Castellano; Alberto Garaventa; Alessandro Moretta; Cristina Bottino; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

9.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

Review 10.  New B7 Family Checkpoints in Human Cancers.

Authors:  Ling Ni; Chen Dong
Journal:  Mol Cancer Ther       Date:  2017-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.